- Home
- SONO vs AMPH Comparison
SONO vs AMPH Comparison
Compare SONO & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONO
- AMPH
- Stock Information
- Founded
- SONO 2002
- AMPH 1996
- Country
- SONO United States
- AMPH United States
- Employees
- SONO N/A
- AMPH N/A
- Industry
- SONO Consumer Electronics/Video Chains
- AMPH Biotechnology: Pharmaceutical Preparations
- Sector
- SONO Consumer Discretionary
- AMPH Health Care
- Exchange
- SONO Nasdaq
- AMPH Nasdaq
- Market Cap
- SONO 1.4B
- AMPH 2.5B
- IPO Year
- SONO 2018
- AMPH 2014
- Fundamental
- Price
- SONO $12.96
- AMPH $51.45
- Analyst Decision
- SONO Hold
- AMPH Buy
- Analyst Count
- SONO 3
- AMPH 4
- Target Price
- SONO $15.67
- AMPH $63.00
- AVG Volume (30 Days)
- SONO 1.3M
- AMPH 268.7K
- Earning Date
- SONO 11-13-2024
- AMPH 11-06-2024
- Dividend Yield
- SONO N/A
- AMPH N/A
- EPS Growth
- SONO N/A
- AMPH 62.07
- EPS
- SONO N/A
- AMPH 3.15
- Revenue
- SONO $1,567,823,000.00
- AMPH $712,891,000.00
- Revenue This Year
- SONO N/A
- AMPH $18.04
- Revenue Next Year
- SONO N/A
- AMPH $4.41
- P/E Ratio
- SONO N/A
- AMPH $16.26
- Revenue Growth
- SONO N/A
- AMPH 31.80
- 52 Week Low
- SONO $10.10
- AMPH $36.56
- 52 Week High
- SONO $19.76
- AMPH $65.92
- Technical
- Relative Strength Index (RSI)
- SONO 60.67
- AMPH 59.40
- Support Level
- SONO $12.76
- AMPH $49.38
- Resistance Level
- SONO $13.19
- AMPH $51.84
- Average True Range (ATR)
- SONO 0.36
- AMPH 1.25
- MACD
- SONO 0.06
- AMPH 0.10
- Stochastic Oscillator
- SONO 93.84
- AMPH 78.90
About SONO Sonos Inc.
Sonos Inc is engaged in providing home sound systems. The company's product profile includes speaker sets and other accessories like boost, mounts, stands, and cables and networking. Geographically, the company operates in the Americas, Europe, the Middle East and Africa, and the Asia Pacific. Generating a majority of its revenue from the Americas.
About AMPH Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.